Optimized bio-synchronous bioactive agent delivery system
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61M-005/00
A61M-005/172
A61M-005/30
G06F-019/00
G16H-010/20
출원번호
US-0156998
(2014-01-16)
등록번호
US-10105487
(2018-10-23)
발명자
/ 주소
DiPierro, Guy
Levy, Alan Joel
출원인 / 주소
CHRONO THERAPEUTICS INC.
대리인 / 주소
Shay Glenn LLP
인용정보
피인용 횟수 :
0인용 특허 :
130
초록▼
Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agen
Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.
대표청구항▼
1. A method for delivering a drug to a patient according to a bio-synchronous drug delivery protocol, the method comprising: initiating the bio-synchronous drug delivery protocol wherein the bio-synchronous drug delivery protocol includes use of a bio-synchronous bioactive agent delivery device to a
1. A method for delivering a drug to a patient according to a bio-synchronous drug delivery protocol, the method comprising: initiating the bio-synchronous drug delivery protocol wherein the bio-synchronous drug delivery protocol includes use of a bio-synchronous bioactive agent delivery device to administer a dose of the drug to the patient;gathering patient data with the bio-synchronous bioactive agent delivery device during the bio-synchronous drug delivery protocol; andobtaining a psychological support based on the patient data. 2. The method for optimized bio-synchronous drug delivery according to claim 1, wherein the at least one bioactive agent is chosen from the group consisting of alprazolam, apomorphine, azelastine, buprenorphine, bupropion, clonidine, enalpril, estradiol, ethinyl estradiol, fentanyl, granisetron, insulin, lidocaine, memantine, methylphenidate, methamphetamine, nitroglycerine, nicotine, norethisterone acetate (NETA), norelgestromine, oxybutynin, pergolide, phenteramine, pramipexole, ramipril, ropinirole, rotigotine, scopolamine, selegiline, tecrine, testosterone, timolol and tolterodine. 3. The method of claim 1, wherein patient data includes patient emotional state data. 4. The method of claim 3, wherein patient emotional state data includes cravings. 5. The method of claim 3, wherein patient emotional state data includes anxiety. 6. The method of claim 1, further comprising: receiving an indication of a craving input to a smart phone, tablet, or computer by the patient. 7. The method of claim 1, wherein patient data includes patient physiological data. 8. The method of claim 7, wherein the patient physiological data is gathered using physiological sensors on the bio-synchronous bioactive agent delivery device. 9. The method of claim 1, wherein the psychological support includes emotional support. 10. The method of claim 9, further comprising: providing the emotional support. 11. The method of claim 10, wherein emotional support is provided after receiving an indication from the patient of a need for treatment. 12. The method of claim 10, wherein the emotional support is provided by a text message, supportive tip, vibrating tone, e-mail, call, or voicemail message. 13. The method of claim 1, further comprising: determining based on gathered patient data whether modification to the bio-synchronous drug delivery protocol is required; andresponsive to determining modification to the bio-synchronous drug delivery protocol is required, modifying the bio-synchronous drug delivery protocol and use of the bio-synchronous bioactive agent delivery device. 14. The method of claim 13, wherein modifying includes remotely adjusting the bio-synchronous treatment protocol. 15. The method of claim 14, further comprising: a healthcare provider remotely adjusting the bio-synchronous treatment protocol. 16. The method of claim 15, wherein remotely adjusting includes delivering the bioactive agent and/or providing emotional support. 17. The method of claim 1, wherein patient data includes compliance with the bio-synchronous drug delivery protocol. 18. The method of claim 1, further comprising: determining patient compliance with the bio-synchronous drug delivery protocol. 19. The method of claim 18, further comprising: analyzing patient compliance during the bio-synchronous drug delivery protocol. 20. The method of claim 19, wherein analyzing patient compliance includes determining bio-synchronous bioactive agent delivery device contact with a skin of the patient. 21. The method of claim 19, wherein analyzing patient compliance includes one or more of determining whether the bio-synchronous bioactive agent delivery device was removed, a treatment in the bio-synchronous drug delivery protocol was missed, or if the bio-synchronous drug delivery protocol was interrupted. 22. The method of claim 19, further comprising upon determination of a non-compliant event: sending an automated message to encourage the patient or sending a message to a healthcare provider. 23. The method of claim 19, wherein patient compliance includes: time of administration of the bioactive agent, a dosage amount of the bioactive agent, and a time at which dosing ceased. 24. The method of claim 1, further comprising: receiving patient data on a smart phone application. 25. The method of claim 1, further comprising: the drug delivery device transmitting patient data wirelessly to a smartphone, tablet, or computer. 26. The method of claim 1, further comprising: the drug delivery device transmitting patient data to a wireless network. 27. The method of claim 1, wherein the bio-synchronous drug delivery protocol includes a psychological support program. 28. The method of claim 1, further comprising: modifying the bio-synchronous drug delivery protocol and use of the bio-synchronous bioactive agent delivery device in response to a determination of a non-compliant event or receiving an indication of a craving input.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (130)
Yanaki, Jamal S., Active transdermal medicament patch and circuit board for same.
DiPierro, Guy; Giannos, Steven A., Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, Alzheimer'S disease, sleep disorders, Parkinson'S disease, AIDS, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like.
Dipierro, Guy; Giannos, Steven A., Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like.
Nagy Christa F. (Wyckoff NJ) Quick Timothy W. (Clifton NJ) Shapiro Stanley S. (Livingston NJ), Compositions of retinoic acids and tocopherol for prevention of dermatitis.
Hall Bonnie J. (Mason OH) Baur Julie A. (Fairfield OH) Deckner George E. (Cincinnati OH), Dermatological compositions and method of treatment of skin lesions therewith using benzoyl peroxide and tocopherol este.
Fallon Renee A. (Sunnyvale CA) Wilson Donald R. (San Francisco CA), Device for administering drug transdermally which provides an initial pulse of drug.
Lattin Gary A. (Forest Lake MN) Dickson Dale A. (Fridley MN) Grace Michael J. (Coon Rapids MN), Electrotransport agent delivery device having a disposable component and a removable liner.
Orr,Kevin H.; Mankaruse,George S.; Asaria,Ali, Handheld electronic device including vibrator having different vibration intensities and method for vibrating a handheld electronic device.
Klug Reja B. (30 Bay Dr. SE. Fort Walton Beach FL 32548) Ford Richard D. (117 Lake Lorraine Cir. Shalimar FL 32579) Jamison Keith A. (137 Indian Bayou Dr. Destin FL 32541) Stearns Ronald E. (2 Caswel, High energy coaxial cable for use in pulsed high energy systems.
Behar Albert (Reston VA) Behar Orna (Reston VA) Frederiksen Lee W. (McLean VA) Howard-Link Donald A. (Columbia MD) Timmerman Catherine (Washington DC), Human behavior modification which establishes and generates a user adaptive withdrawal schedule.
Edwards, Eric S.; Edwards, Evan T.; Licata, Mark J.; Meyers, Paul F.; Weinzierl, David A., Medicament delivery device having an electronic circuit system.
Segel Joseph M. ; Samuelson Michael H., Method and system for stopping or modifying undesirable health-related behavior habits or maintaining desirable health-.
Cormier Michel J. N. (Palo Alto CA) Ledger Philip W. (Mountain View CA) Amkraut Alfred (Palo Alto CA) Marty Jean P. (Sceaux FRX), Method for reducing sensitization or irritation in transdermal drug delivery and means therefor.
Majeed, Muhammed; Badmaev, Vladimir; Bammi, Rajinder Kumar; Prakash, Subbalakshmi; Natarajan, Sankaran, Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives.
Raheman, Fazal, Prescription zero: a non-pharmaceutical prescription device for prescribing, administering, monitoring, measuring and motivating a therapeutic lifestyle regimen for prevention and treatment of chronic diseases.
Amkraut Alfred (Palo Alto CA) Shaw Jane E. (Atherton CA), Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug.
Ledger Philip W. (Mountain View CA) Cormier Michel J. (Mountain View CA) Amkraut Alfred (Palo Alto CA), Reduction or prevention of sensitization to drugs.
Cormier Michel J-N (Mountain View CA) Ledger Philip W. (Mountain View CA) Amkraut Alfred (Palo Alto CA), Reduction or prevention of skin irritation by drugs.
Cormier Michel (Mountain View CA) Amkraut Alfred (Palo Alto CA) Ledger Philip W. (Bedford GBX), Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensiti.
Osborne James L. (Mountain View CA) Nelson Melinda (Sunnyvale CA) Enscore David J. (Saratoga CA) Yum Su I. (Los Altos CA) Gale Robert M. (Los Altos CA), Subsaturated nicotine transdermal therapeutic system.
Currie, John F.; Paranjape, Makarand; Peck, Carl C.; White, Robert; Schneider, Thomas W., Systems and methods for monitoring health and delivering drugs transdermally.
Haak Ronald P. (Menlo Park CA) Theeuwes Felix (Los Altos Hills CA) Gyory J. Richard (San Jose CA) Lattin Gary A. (Forest Lake MN), Transdermal delivery device.
Bello Gastone P. (Monmouth Beach NJ) Lyle John W. (Belmar NJ) Johnson Donald A. (Sea Girt NJ), Transdermal drug delivery device and method for its manufacture.
Fallon Renee A. (Sunnyvale CA) Venkatraman Subbu S. (Palo Alto CA) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset.
Venktrama Subbu S. (Palo Alto CA) Fallon Renee A. (Sunnyvale CA) Cleary Gary W. (San Mateo CA), Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset.
Govil Sharad K. (Plantation FL) Rudnic Edward M. (Boca Raton FL) Sterner Dale G. (Pembroke Pines FL), Transdermal nitroglycerin patch with penetration enhancers.
Quan Danyi (Salt Lake City UT) Deshpanday Ninad A. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT), Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
Kang, Sewon; Fisher, Gary J.; Voorhees, John J., Use of natural EGFR inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth factor receptor.
Heiber Werner (Bedford Hills NY) Andriola Robert (Putnam Valley NY) Williams Paul (Fairlawn NJ) Ebert Charles (Redwood City CA), User-activated transdermal therapeutic system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.